Patent ID: 11903918
Assignee: BANNER LIFE SCIENCES LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method for treating or reducing symptoms of multiple sclerosis or psoriasis in a subject comprising orally administering to a subject in need thereof one or more pharmaceutical dosage forms comprising:
(a) a single dosage form comprising about 90 mg to about 100 mg of monomethyl fumarate in an immediate releasing single-phase non-aqueous liquid vehicle, wherein administration to the subject provides an effective dosage for the treatment of multiple sclerosis or psoriasis, wherein the incidence of an at least moderate severity gastrointestinal adverse event is at least 5% less frequent and the incidence of vomiting and diarrhea is at least 5% less frequent, as compared to a 120 mg dose of dimethyl fumarate; or
(b) contemporaneously administering two dosage forms comprising about 85 mg to about 100 mg of monomethyl furmate ot a single dosage form comprising about 170 mg to about 200 mg of monomethyl fumarate in an immediate releasing single-phase non-aqueous liquid vehicle, wherein administration to the subject provides an effective dosage for the treatment of multiple sclerosis or psoriasis, wherein the incidence of an at least moderate severity gastrointestinal adverse event is at least 5% less frequent and the incidence of vomiting and diarrhea is at least 5% less frequent, as compared to a 240 mg dose of dimethyl fumarate; and
wherein on average the subject experiences a modified Overall Gastrointestinal Symptom Scale (MOGISS) score of ≤4 for GI events earlier in treatment than would occur in treatment with dimethyl furmate.